Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
Novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide free base and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, pharmaceutical compositions thereof and methods of their preparation and use are disclosed herein.
1. A crystalline form of ponatinib characterized by an x-ray powder diffraction pattern comprising at least three 2θ values (±0.3) chosen from 5.0; 6.5; 9.5; 12.0; 12.5; 14.0; 15.0; 16.5; 17.2; 18.4; 20.0; 21.0; 22.8; 23.5; and 24.6; and 29.5.
2. The crystalline form of ponatinib of claim 1 , wherein the x-ray powder diffraction pattern comprises at least three 2θ values (±0.3) chosen from 5.0; 6.5; 9.5; 12.0; 14.0; 15.0; 16.5; 17.2; 18.4; 20.0; 22.8; 24.6; and 29.5.
3. The crystalline form of ponatinib of claim 1 , wherein the x-ray powder diffraction pattern comprises at least four 2θ values (±0.3) chosen from 5.0; 6.5; 9.5; 12.0; 14.0; 15.0; 16.5; 17.2; 18.4; 20.0; 22.8; 24.6; and 29.5.
4. The crystalline form of ponatinib of claim 3 , wherein the x-ray powder diffraction pattern comprises at least five 2θ values (±0.3) chosen from 5.0; 6.5; 9.5; 12.0; 14.0; 15.0; 16.5; 17.2; 18.4; 20.0; 22.8; 24.6; and 29.5.
5. The crystalline form of ponatinib of claim 4 , wherein the x-ray powder diffraction pattern comprises at least six 2θ values (±0.3) chosen from 5.0; 6.5; 9.5; 12.0; 14.0; 15.0; 16.5; 17.2; 18.4; 20.0; 22.8; 24.6; and 29.5.
6. The crystalline form of ponatinib of claim 5 , wherein the x-ray powder diffraction pattern comprises at least seven 2θ values (±0.3) chosen from 5.0; 6.5; 9.5; 12.0; 14.0; 15.0; 16.5; 17.2; 18.4; 20.0; 22.8; 24.6; and 29.5.
7. The crystalline form of ponatinib of claim 1 , wherein the x-ray powder diffraction pattern comprises a 2θ value at 9.5±0.3 and further comprises at least three 2θ values (±0.3) chosen from 12.0; 14.0; 15.0; 16.5; and 17.2.
8. The crystalline form of ponatinib of claim 1 , wherein the x-ray powder diffraction pattern comprises a 2θ value at 9.5±0.3, a 2θ value at 14.0±0.3, and at least two 2θ values (±0.3) chosen from 12.0; 15.0; 16.5; and 17.2.
9. A composition comprising the crystalline form of ponatinib of claim 1 , and a pharmaceutically acceptable carrier.
10. A method for treating chronic myeloid leukemia in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the crystalline form of ponatinib of claim 1 .
11. The method of claim 10 , wherein the subject has chronic phase chronic myeloid leukemia.
12. The method of claim 10 , wherein the subject has acute phase chronic myeloid leukemia.
13. The method of claim 10 , wherein the subject has blast phase chronic myeloid leukemia.
14. The method of claim 10 , wherein the subject has chronic phase, acute phase, or blast phase chronic myeloid leukemia with resistance or intolerance to at least one prior tyrosine-kinase inhibitor.
15. The method of claim 14 , wherein the subject has chronic phase, acute phase, or blast phase chronic myeloid leukemia with resistance or intolerance to at least two prior tyrosine-kinase inhibitors.
16. The method of claim 14 , wherein the leukemia results from a mutation in the Bcr-Abl kinase domain.
17. A method for treating Philadelphia chromosome positive acute lymphoblastic leukemia in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the crystalline form of ponatinib of claim 1 .
18. The method of claim 17 , wherein the leukemia results from a mutation in the Bcr-Abl kinase domain.